Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer

被引：15

作者：

Badovinac, Sonja ^{[1
]}

Korsic, Marta ^{[1
]}

Zarkovic, Kamelija ^{[2
]}

Mursic, Davorka ^{[1
]}

Roglic, Mihovil ^{[1
]}

Jakopovic, Marko ^{[1
]}

Samarzija, Miroslav ^{[1
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Lung Dis Jordanovac, Jordanovac 104, Zagreb 10000, Croatia

[2] Univ Hosp Ctr Zagreb, Dept Pathol, Zagreb, Croatia

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 06期

关键词：

immune-related adverse event; immunotherapy; lung cancer; myositis; nivolumab; ADVERSE EVENTS; METASTATIC MELANOMA; ANTIGEN-4; BLOCKADE; MYASTHENIA-GRAVIS; IPILIMUMAB; RHABDOMYOLYSIS; MYOPATHY;

D O I：

10.2217/imt-2017-0174

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: Alongside the proven efficacy, immunotherapy in treatment of malignant diseases can cause immune-related adverse events different from commonly known chemotherapy-related toxicities. Case presentation: During nivolumab treatment of metastatic squamous cell lung cancer, the patient developed a symptomatic inflammatory myositis confirmed with muscle biopsy and primary hypothyroidism. After initiation of corticosteroids and thyroid hormone replacement, the clinical and laboratory improvement occurred. To the best of our knowledge, this is the first description of a case of nivolumab-induced synchronous manifestation of immune-related myositis and hypothyroidism. Conclusion: Immunotherapy can trigger a wide spectrum of immune-related adverse events that could occur simultaneously. If not detected and treated, these events could become severe or even fatal and require clinicians' awareness and routine check-ups.

引用

页码：427 / 431

页数：5

共 19 条

[1] Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade [J].

Ali, Shirwa Sheik ;

Goddard, Allison L. ;

Luke, Jason J. ;

Donahue, Hilary ;

Todd, Derrick J. ;

Werchniak, Andrew ;

Vleugels, Ruth Ann .

JAMA DERMATOLOGY, 2015, 151 (02) :195-199

[2] Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody [J].

Bilen, Mehmet Asim ;

Subudhi, Sumit K. ;

Gao, Jianjun ;

Tannir, Nizar M. ;

Tu, Shi-Ming ;

Sharma, Padmanee .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4

[3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[4] Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma Case report [J].

Chen, Yu-Hsiu ;

Liu, Feng-Cheng ;

Hsu, Chang-Hung ;

Chian, Chih-Feng .

MEDICINE, 2017, 96 (27)

[5] Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases [J].

de Chabot, G. ;

Justeau, G. ;

Pinquie, F. ;

Nadaj-Pakleza, A. ;

Hoppe, E. ;

Hureaux, J. ;

Urban, T. .

REVUE DE PNEUMOLOGIE CLINIQUE, 2017, 73 (06) :326-330

[6] Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

[7] A Case of Nivolumab-Induced Myositis [J].

Fox, Eric ;

Dabrow, Michael ;

Ochsner, Greg .

ONCOLOGIST, 2016, 21 (12) :E3-E3

[8] Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes [J].

Freeman-Keller, Morganna ;

Kim, Youngchul ;

Cronin, Heather ;

Richards, Allison ;

Gibney, Geoffrey ;

Weber, Jeffrey S. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :886-894

[9] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Haanen, J. B. A. G. ;

Carbonnel, F. ;

Robert, C. ;

Kerr, K. M. ;

Peters, S. ;

Larkin, J. ;

Jordan, K. .

ANNALS OF ONCOLOGY, 2017, 28 :119-142

[10] Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab [J].

Hunter, Gary ;

Voll, Chris ;

Robinson, Christopher A. .

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2009, 36 (04) :518-520

← 1 2 →